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Coronavirus disease 2019 (COVID- 19) is a pan-demic viral disease with its origin in Wuhan, China, in December 2019.1 As of March 20, 2020, 
244 602 patients have tested positive worldwide; and 
10  031 (4.1%) of these patients were reported to be 
deceased because of COVID- 19.2 According to the 
Chinese Center for Disease Control and Prevention, 
as of February 11, 2020 with 44  672 confirmed pa-
tients, several comorbidities, including cardiovascular 
diseases and diabetes mellitus, seem to be involved in 
COVID- 19 patients with a severe course.3 In this largest 
analysis, 10.5% of fatal cases occurred in patients with 
cardiovascular disease and 6% in patients with arterial 
hypertension.3 It is unclear whether these comorbidi-
ties contribute to the higher risk.
See Article by Guo et al.
Most patients with cardiovascular comorbidities 
qualify for angiotensin- converting enzyme inhibitor 
(ACEI) or angiotensin II receptor blocker (ARB) therapy.4 
Of note, Severe acute respiratory syndrome coronavi-
rus 2 (SARS- CoV- 2) uses the receptor angiotensin- 
converting enzyme (ACE) 2 for entry into target cells.5 
Ferrario et al reported that both ACEI and ARB could 
significantly increase mRNA expression of cardiac 
ACE2.6 On the basis of these thoughts, we recently 
generated the hypothesis that these drugs might play 
a role in the severe course of COVID- 19 cases.7 More 
importantly, no clinical- epidemiological data have been 
put forward and it is unknown whether the hypothe-
sized mechanism plays a pivotal role in COVID- 19.
The lay press picked up the theory, causing con-
cern and even anxiety among patients and their 
healthcare providers. Because of the lack of cur-
rent evidence of a potential negative impact of these 
medications on COVID- 19, we currently support the 
position statement of the European and American 
Societies of Cardiology, who express that ACEIs and 
ARBs are safe and should be continued and pre-
scribed according to established guidelines.8,9
HIGH MORTALITY IN COVID- 19: 
CAUSED BY PRE- EXISTING 
CARDIOVASCULAR DISEASE, ACEI/
ARBS MEDICATION, OR BOTH?
A recently published single- center study on 99 hos-
pitalized patients in China showed that 40% of the 
cohort had cardiovascular or cerebrovascular disease 
and 12% had diabetes mellitus.10 In another Chinese 
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report from 138 hospitalized COVID- 19 patients, 31% 
had hypertension, 10% had diabetes mellitus, and 
14.5% had cardiovascular disease, being the 3 most 
common comorbidities.11 In the latter study, 36 of the 
138 patients needed intensive care unit stays, and 
58.3% of all intensive care unit patients were reported 
to have hypertension and 22.1% were reported to have 
diabetes mellitus.
Beyond these studies, Zhou et al have recently pub-
lished a study on the risk factors for adult inpatients 
who die from COVID- 19.12 Notably, of 58 patients with 
arterial hypertension, 26 (45%) died. This number was 
significantly higher than the 54 of 191 (28%) from the 
entire case series. Even more impressive was the fact 
that 13 of 15 (87%) of the patients with coronary heart 
disease died, as well as 17 of 36 (47%) with diabe-
tes mellitus.12 Unfortunately, in our opinion, no studies 
have been published to date that make an adequate 
adjustment of cardiovascular risk factors for important 
covariates. An overview of previous data with adjust-
ment is shown in the Table.
According to the latest analysis of the National 
Health and Nutrition Examination Survey ACEIs/ARBs 
are the most prevalent antihypertensive medication 
among all drug classes.14 Unfortunately, the European 
Centre for Disease Prevention and Control does not 
record any previous drugs in its data collection on 
COVID- 19 patients.15 Until now, no data are available 
about the association between previous drug intake 
and severity of COVID- 19 pulmonary outcome. This 
brings up 4 key questions:
1. Are these cardiovascular comorbidities simply con-
founders (as they occur frequently with higher age 
and have been shown to predispose to worse 
outcome with influenza type A H1N1 infection)?
2. Is there is a link between the comorbidities and 
SARS-CoV-2 (ie, are patients with heart failure at a 
higher risk of pulmonary outcome)?
3. Does the comorbidities-associated intake of some 
drug classes improve or worsen infectivity or the 
course of COVID-19?
4. If, (and this is a big if), renin-angiotensin system 
blockade emerges in one way or another as a pos-
sible mediator, are there difference between ACEIs 
and ARBs?
In this issue of the Journal of the American Heart 
Association (JAHA), Guo et al16 point out 2 important is-
sues: On the one hand, the possible overregulation of 
ACE2 leads to an increased risk of infection of the pul-
monary (and possibly other) tissues. On the other hand, 
there is evidence that there exist both cardio protective 
and pulmonary- protective activity of ACE2. Which is the 
case?
Several demographic characteristics are associ-
ated with increased ACE2 expression, such as older 
age and male sex.17,18,19 In animal studies, ACEIs and 
ARBs have been shown in rodents to increase the 
expression of ACE2 mRNA in different organs and 
tissues, including heart, kidney, and the aorta.9,20,21 
In a study with healthy humans treated with ACEIs 
and controls, the mean duodenal mRNA expression 
level of ACE2 was increased 1.9- fold when com-
pared with nontreated controls. However, no signifi-
cant differences in expression levels were observed 
in patients treated with ARBs.22 Beside age and sex, 
arterial hypertension and diabetes mellitus may up-
regulate ACE2.18,23,24 On the contrary, it seems that 
once infection and acute respiratory distress syn-
drome ensue, a downregulation of ACE2 occurs. 
The counterregulatory enzyme ACE2 that degrades 
angiotensin II to angiotensin1–7 has been shown 
Table. Overview of Current Studies With Adjusted COVID- 19 Outcome Analysis for Cardiovascular Risk Factors
Article
Study 
Population
Cardiovascular 
Risk Factor
Association of Risk 
Factor With Fatal 
Outcome
Adjusted 
Association With 
Fatal Outcome Adjusted for Comment
Zhou et al, 
Lancet12
n=191 Coronary heart 
disease
2/137 (Survivor) vs 
13/54 (non- survivor), 
OR 21.4 (95% CI, 
4.6–98.8, P<0.001
OR, 2.14 (95% CI, 
0.26–17.8; P=0.48)
Lymphocyte 
count, d- dimer, 
Sequential 
Organ Failure 
Assessment 
(SOFA) score, 
age
Sample size too 
small for meaningful 
adjustment
Caramelo et al, 
medRxiv13
Simulation, 
based on 
Chinese Center 
for Disease 
Control and 
Prevention 
(CCDC) report3
Hypertension Not available OR, 7.41 (95% CI, 
6.33–8.80)
Age, sex Results obtained 
by Monte- Carlo 
simulation, not peer 
reviewed
ccdc indicates Chinese Center for Disease Control and Prevention; COVID-19 indicates coronavirus disease 2019; sofa: Sequential Organ Failure Assessment; 
and OR, odds ratio.
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to be beneficial in acute respiratory distress syn-
drome when replaced, and may offer a novel treat-
ment option.25,26 Similarly, in animal studies, ACEIs/
ARBs have been shown to upregulate ACE2 activity; 
thereby, they may possibly be favorable once pa-
tients are infected with COVID- 19.6,25
At present, we cannot rule out that long- term in-
take of ACEIs and/or ARBs may facilitate SARS- CoV- 2 
entry and virus replication. Conversely, it is yet un-
known whether intake of ACEIs and/or ARBs, when 
infected, is beneficial with regard to pulmonary out-
come. Possibly, we are dealing here with a double- 
edged sword, depending on the phase of the disease: 
increased baseline ACE2 expression could potentially 
increase infectivity and ACEI/ARB use would be an ad-
dressable risk factor. Conversely, once infected, down-
regulation of ACE2 may be the hallmark of COVID- 19 
progression. Consequently, upregulation by prefer-
entially using renin- angiotensin system blockade and 
ACE2 replacement in the acute respiratory syndrome 
phase may turn out to be beneficial.
Regardless of these deliberations, we would like 
to emphasize that many older patients are on renin- 
angiotensin system blockade because of latent or 
manifest left ventricular dysfunction and that discon-
tinuation of these drugs may exacerbate frank heart 
failure. There is little doubt that heart failure is prone to 
have an unfavorable effect on pulmonary outcome in 
the course of COVID- 19.
In conclusion, cardiovascular diseases and/or their 
therapy, by affecting ACE2 levels, may play a pivotal 
role with regard to infectivity and outcome of COVID- 19. 
Whether treatment or disease induced  upregulation 
of ACE2 influences the course of COVID-19 urgently 
needs to be determined.
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